Related Experiment Video

Updated: Nov 5, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

Protein kinase inhibitors for the treatment of prostate cancer

Vincent Chau1, Ravi A Madan1, Jeanny B Aragon-Ching2,3

  • 1Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Expert Opinion on Pharmacotherapy
|May 14, 2021
PubMed
Abstract

Insights

Protein kinase inhibitors show promise for metastatic prostate cancer, but none have FDA approval yet. Further research into resistance mechanisms and combination therapies is crucial for successful kinase inhibition in prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Protein kinases are key targets in metastatic prostate cancer due to their role in tumor growth and spread.
  • Various protein kinase inhibitors targeting pathways like BCR-ABL, CSF1R, VEGF/VEGFR, and PI3K have been investigated.
  • Cabozantinib and ipatasertib show promise in specific prostate cancer patient populations.

Purpose of the Study:

  • To review early and late-phase clinical trials of protein kinase inhibitors in prostate cancer.
  • To summarize the current landscape of kinase inhibitor research in prostate cancer.

Main Methods:

  • Literature review of clinical trials.
  • Analysis of ongoing and completed studies involving protein kinase inhibitors for prostate cancer.

Main Results:

  • Multiple kinase inhibitors have demonstrated promising results in clinical trials for prostate cancer.
  • No protein kinase inhibitors have received FDA approval for prostate cancer treatment to date.
  • Several drug candidates have unfortunately failed to meet primary endpoints in clinical trials.

Conclusions:

  • Despite promising early results, challenges remain in achieving FDA approval for kinase inhibitors in prostate cancer.
  • Understanding resistance mechanisms and optimizing combination therapy trial designs are essential for future success.
  • Ongoing studies are evaluating promising drug candidates, with potential for improved outcomes in prostate cancer treatment.
Keywords:
Prostate canceripatasertibmetastatic castration-resistant prostate cancerprotein kinase inhibitors

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.3K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
302
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
302
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
299